Asthma and COPD

被引:39
作者
Welte, Tobias
Groneberg, David A.
机构
[1] Hannover Med Sch, Abt Pneumol, Zentrum Innere Med, Dept Resp Med, D-30625 Hannover, Germany
[2] Free Univ Berlin, Charite Sch Med, Allergy Ctr Charite, D-13353 Berlin, Germany
[3] Humboldt Univ, D-13353 Berlin, Germany
关键词
airways; asthma; COPD; drug; inflammation; lung; therapy;
D O I
10.1016/j.etp.2006.02.004
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The two obstructive airway diseases bronchial asthma and chronic obstructive pulmonary disease (COPD) represent major global causes of disability and death, and COPD is estimated to become the third most common cause of death by 2020. The structural and pathophysiologic findings in both diseases appear to be easily differentiated in the extremes of clinical presentation. However, a significant overlap may exist in individual patients regarding features such as airway wall thickening on computer tomography or reversibility and airway hyperresponsiveness in lung function tests. Airway inflammation differs between the two diseases. In bronchial asthma, airway inflammation is characterized in most cases by an increased number of activated T-lymphocytes, particularly CD4 + Th2 cells, and sometimes eosinophils and mast cells. The most notable difference of chronic severe asthma compared with mild to moderate asthma is an increased number of neutrophils. In stable COPD, airway inflammation is characterized by an increased number of T-lymphocytes, particularly CD8 + T cells, macrophages and neutrophils. With the progression of the disease severity, macrophage and neutrophil numbers increase. Although there may be a partial overlap between asthma and COPD in some patients, the differences in functional, structural and pharmacological features clearly demonstrate the consensus that asthma and COPD are different diseases along all their stages of severity. (c) 2006 Elsevier GmbH. All rights reserved.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 58 条
[1]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[2]   Bronchodilator reversibility testing in chronic obstructive pulmonary disease [J].
Calverley, PMA ;
Burge, PS ;
Spencer, S ;
Anderson, JA ;
Jones, PW .
THORAX, 2003, 58 (08) :659-664
[3]   Is there a difference between chronic airway inflammation in chronic severe asthma and chronic obstructive pulmonary disease? [J].
Caramori, G ;
Pandit, A ;
Papi, A .
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 5 (01) :77-83
[4]   Population impact of different definitions of airway obstruction [J].
Celli, BR ;
Halbert, RJ ;
Isonaka, S ;
Schau, B .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (02) :268-273
[5]   The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease [J].
Celli, BR ;
Cote, CG ;
Marin, JM ;
Casanova, C ;
de Oca, MM ;
Mendez, RA ;
Pinto Plata, V ;
Cabral, HJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (10) :1005-1012
[6]   Assessing the burden of respiratory disease in the UK [J].
Chung, F ;
Barnes, N ;
Allen, M ;
Angus, R ;
Corris, P ;
Knox, A ;
Miles, J ;
Morice, A ;
O'Reilly, J ;
Richardson, M .
RESPIRATORY MEDICINE, 2002, 96 (12) :963-975
[7]  
Chung KF, 2004, NEW ENGL J MED, V351, P1459
[8]   Cytokines in chronic obstructive pulmonary disease [J].
Chung, KF .
EUROPEAN RESPIRATORY JOURNAL, 2001, 18 :50S-59S
[9]   Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease [J].
Fabbri, LM ;
Romagnoli, M ;
Corbetta, L ;
Casoni, G ;
Busljetic, K ;
Turato, G ;
Ligabue, G ;
Ciaccia, A ;
Saetta, M ;
Papi, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (03) :418-424
[10]   NATURAL-HISTORY OF CHRONIC AIR-FLOW OBSTRUCTION [J].
FLETCHER, C ;
PETO, R .
BMJ-BRITISH MEDICAL JOURNAL, 1977, 1 (6077) :1645-1648